Research progress of pyrazinamide in the treatment of drug-resistant tuberculosis

Pyrazinamide (pyrazinamide) is a nicotinamide analog. As a unique treatment for tuberculosis, antimicrobial drugs have shortened the treatment time, improved the efficiency of treatment, and reduced the recurrence rate, which is different from other common anti-tuberculosis drugs by inhibiting multiple targets, such as energy production, reverse translation, and survival pantothenate/coenzyme A. Therefore, it is used as an irreplaceable part of the second-line treatment of multidrug-resistant tuberculosis. In recent years, a combination of multiple anti-tuberculosis drugs, such as pyrazinamide and rifampin, has been found to improve the radical cure rate of tuberculosis. This review discusses the recent developments in pyrazinamide.

Publication Details

Journal
Academic Journal of Medicine & Health Sciences
Published
2025-01-01
DOI
https://doi.org/10.25236/ajmhs.2025.060204
Citations
1
Primary Topic
Tuberculosis Research and Epidemiology
Type
article
Field-Weighted Citation Impact
1.40
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Research progress of pyrazinamide in the treatment of drug-resistant tuberculosis

1 citations
Academic Journal of Medicine & Health Sciences
Tuberculosis Research and Epidemiology
1.40
article

Research progress of pyrazinamide in the treatment of drug-resistant tuberculosis

article en
1 citations

Abstract

Pyrazinamide (pyrazinamide) is a nicotinamide analog. As a unique treatment for tuberculosis, antimicrobial drugs have shortened the treatment time, improved the efficiency of treatment, and reduced the recurrence rate, which is different from other common anti-tuberculosis drugs by inhibiting multiple targets, such as energy production, reverse translation, and survival pantothenate/coenzyme A. Therefore, it is used as an irreplaceable part of the second-line treatment of multidrug-resistant tuberculosis. In recent years, a combination of multiple anti-tuberculosis drugs, such as pyrazinamide and rifampin, has been found to improve the radical cure rate of tuberculosis. This review discusses the recent developments in pyrazinamide.

Academic Journal of Medicine & Health SciencesVol. 6(2)
Good health and well-being
Openalex Percentile: Top 22%
Tuberculosis Research and Epidemiology
1.40
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.